Where does David Grayzel work?

David Grayzel is Managing Director at Atlas Venture and Board director at Xilio Therapeutics and Board director at Affinia Therapeutics.

What does David Grayzel invest in?

David Grayzel invests in Biotech, Healthtech.

What check size does David Grayzel write?

David Grayzel typically writes checks of $500K – $5M.

What boards does David Grayzel sit on?

David Grayzel holds tracked board seats at Aerovate, Aerovate Therapeutics, Inc., Affinia Therapeutics, Affinia Therapeutics, Akriveia Therapeutics, Annovation Biopharma, Arteaus Therapeutics, Cadent Therapeutics, Comanche Biopharma, Comanche Biopharma.

Where did David Grayzel go to school?

David Grayzel studied at Harvard Medical School (MD); Stanford University (BA).

David Grayzel

Investor

Managing Director at Atlas Venture · Board director at Xilio Therapeutics · Board director at Affinia Therapeutics

Cambridge, Massachusetts, United States

Writes $500K – $5M checks · typically $2M

About

David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).

Contact· self-published, not guessed

d•••@atlasventure.comreveal

Invests in

BiotechHealthtech

Board director at Xilio Therapeutics

Intro paths

→

In turn, David can intro founders to Xilio Therapeutics's investors below.

Xilio Therapeutics's investors · 11

Atlas VentureCambridge · $500K – $1M checks · since 2021 Bain Capital Life SciencesBoston · since 2021 Bay City CapitalSan Rafael · $5M – $10M checks F-Prime CapitalCambridge · $3M – $10M checks · since 2021 M VenturesLos Angeles · $10.8M checks MRL Ventures FundCambridge · $25M checks RA CapitalBoston RiverVest Venture PartnersSt. Louis · $500K – $3M checks Rock Springs CapitalBaltimore Solasta VenturesBoston SV Health InvestorsBoston · $1M – $20M checks

Co-founders at Xilio Therapeutics

Rene RussoExecutive Officer, Director

Board director at Affinia Therapeutics

Intro paths

→

In turn, David can intro founders to Affinia Therapeutics's investors below.

Affinia Therapeutics's investors · 8

Atlas VentureCambridge · $500K – $1M checks · since 2025 EcoR1 CapitalSan Francisco Eight Roads VenturesMumbai · $5M – $30M checks F-Prime CapitalCambridge · $3M – $10M checks · since 2025 GV (Google Ventures)Mountain View · $250K – $50M checks NEA SecondaryTimonium · since 2025 New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks TCG CrossoverPalo Alto

Co-founders at Affinia Therapeutics

Luc VandenbergheDirector

Aaron Tward, M.D., Ph.D.Scientific Co-Founder

Botond Roska, M.D., Ph.D.Scientific Co-Founder

Luk Vandenberghe, Ph.D.Scientific Co-Founder and Adviser, and Board Member

Experience

Atlas VenturePartnercurrent2014 — presentCambridge, MA
Atlas Venture Development Corp.Managing Directorcurrent2010 — present
Infinity PharmaceuticalsVP Clinical Development and Medical Affairs2002 — 2010
Dyax CorpDirector Corporate Development and Business Operations2000 — 2002
Massachusetts General HospitalIntern, Resident1997 — 2000

Deals · 4

Triana Biomedicines, Inc.Board seat

via Atlas Venture · filed Dec 2025 · $120.1M raise

Xilio TherapeuticsBoard seat

via Atlas Venture · filed Feb 2021 · $95M raise

Aerovate Therapeutics, Inc.Board seat

via Atlas Venture · filed Aug 2020 · $75.8M raise

Akriveia TherapeuticsBoard seat

via Atlas Venture · filed Jan 2018 · $22.5M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

AerovateAffinia Therapeutics Affinia TherapeuticsAnnovation BiopharmaArteaus TherapeuticsCadent TherapeuticsComanche BiopharmaComanche BiopharmaDay One BiopharmaceuticalsDeliniaQ32 BioSurface OncologyTrace NeuroscienceTRIANA BiomedicinesVima Therapeutics

Sources: the firm's website · SEC Form D filings.

Colleagues at Atlas Venture

Aimee Raleigh

Principal at Atlas Venture

Bruce Booth

Partner at Atlas Venture

Chelsea Johnson

Principal at Atlas Venture

Jason Rhodes

Partner at Atlas Venture

Jean-François Formela

Partner at Atlas Venture

Jernej Godec

Principal at Atlas Venture

Jodie Morrison

Venture Partner at Atlas Venture

Josh Powers

Associate at Atlas Venture

Network4

Aimee Raleigh

Principal at Atlas Venture

Bruce Booth

Partner at Atlas Venture

Chelsea Johnson

Principal at Atlas Venture

Jason Rhodes

Partner at Atlas Venture

Investors connected to David in public investor directories — a warm-intro map.

Frequently asked questions

Who is David Grayzel?: David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).
Where does David Grayzel work?: David Grayzel is Managing Director at Atlas Venture and Board director at Xilio Therapeutics and Board director at Affinia Therapeutics.
What does David Grayzel invest in?: David Grayzel invests in Biotech, Healthtech.
What check size does David Grayzel write?: David Grayzel typically writes checks of $500K – $5M.
What boards does David Grayzel sit on?: David Grayzel holds tracked board seats at Aerovate, Aerovate Therapeutics, Inc., Affinia Therapeutics, Affinia Therapeutics, Akriveia Therapeutics, Annovation Biopharma, Arteaus Therapeutics, Cadent Therapeutics, Comanche Biopharma, Comanche Biopharma.
Where did David Grayzel go to school?: David Grayzel studied at Harvard Medical School (MD); Stanford University (BA).